Diffuse Large B-Cell Lymphoma — A Grand Rounds Program

Featuring an interview with Dr Matthew Lunning, including the following topics:Bispecific antibody/antibody-drug conjugate combinations (0:00)A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD, MMSc (8:07)CME information and select publications

Featuring a presentation by Dr Matthew Matasar, including the following topics:Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41)Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01)Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47)Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34)Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31)Discussion of Questions from the Community (50:20)CME information and select publications

Featuring an interview with Dr Matthew Lunning, including the following topics:A woman in her late 70s with non-GCB diffuse large B-cell lymphoma receives pola-R-CHP — Ann LaCasce, MD, MMSc (0:00)CNS prophylaxis in non-Hodgkin lymphoma (7:58)CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics:Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00)Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46)Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37)CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics:Consensus Approach to optimizing front-line treatment (0:00)Emerging role of sonrotoclax (8:39)Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48)Evolving role of minimal residual disease assessment (19:16)CME information and select publications

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)CME information and select publications

Featuring perspectives from Dr Catherine C Coombs, including the following topics:Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42)Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50)Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)CME information and select publications

Featuring perspectives from Dr Catherine C Coombs, including the following topics:Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)CME information and select publications

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:Introduction (0:00)New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33)Potential Role of Cereblon E3 Ligase Modulators and Other Promising Novel Agents and Strategies for R/R MM — Prof Dimopoulos (41:12)CME information and select publications

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:Introduction (0:00)Minimal Residual Disease Assays in Community-Based Practice (1:24)New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)Richter Transformation (30:43)Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)CME information and select publications